BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently ...

In seven patients with Danon disease, a single infusion of adeno-associated virus serotype 9 carrying transgene LAMP2B ...

Dropsy, described in the 17th century, treated with “cure de dechloruration” (bloodletting, leeching, and lancing) and a ...

AI-assisted diagnosis of asymptomatic left ventricular dysfunction may detect disease early and thereby expedite treatment of ...

"The completion of enrollment in the Phase 1/2a trial marks a crucial milestone for this cardiac gene therapy trial in patients with heart failure with reduced ejection fraction (HFrEF).

Medera announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in ...

The following is a summary of "Tissue-tracking mitral annular displacement predicts impaired left ventricular mechanics and ...